They analyzed results from 878 patients, 43% of whom received adjuvant tamoxifen. After a median follow-up of almost 15 years ...

Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

"HR-positive, HER2-negative is the most common type of breast cancer in the United States and we frequently need to decide whether or not adjuvant chemotherapy would be beneficial, and if so ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...

For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cis ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...